Biotron Limited (BITRF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 493.47 Thousand AUD | -88.07% |
| 2023 | 4.13 Million AUD | 116.95% |
| 2022 | 1.9 Million AUD | -55.94% |
| 2021 | 4.32 Million AUD | -44.72% |
| 2020 | 7.82 Million AUD | 33.62% |
| 2019 | 5.85 Million AUD | 261.72% |
| 2018 | 1.61 Million AUD | -21.38% |
| 2017 | 2.05 Million AUD | -40.87% |
| 2016 | 3.48 Million AUD | -24.54% |
| 2015 | 4.61 Million AUD | 147.66% |
| 2014 | 1.86 Million AUD | -61.7% |
| 2013 | 4.86 Million AUD | -42.49% |
| 2012 | 8.46 Million AUD | 219.96% |
| 2011 | 2.64 Million AUD | 42.35% |
| 2010 | 1.85 Million AUD | 74.64% |
| 2009 | 1.06 Million AUD | -53.08% |
| 2008 | 2.26 Million AUD | 49.26% |
| 2007 | 1.51 Million AUD | -68.45% |
| 2006 | 4.81 Million AUD | 98.22% |
| 2005 | 2.42 Million AUD | -21.89% |
| 2004 | 3.1 Million AUD | -47.38% |
| 2003 | 5.9 Million AUD | -31.55% |
| 2002 | 8.63 Million AUD | -15.3% |
| 2001 | 10.19 Million AUD | -75.86% |
| 2000 | 42.22 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 2.49 Million AUD | 30.89% |
| 2024 FY | 493.47 Thousand AUD | -88.07% |
| 2024 Q4 | 493.47 Thousand AUD | 0.0% |
| 2024 Q2 | 2.49 Million AUD | 0.0% |
| 2024 Q3 | 493.47 Thousand AUD | -80.22% |
| 2023 Q2 | 6.67 Million AUD | 0.0% |
| 2023 FY | 4.13 Million AUD | 116.95% |
| 2023 Q1 | 6.67 Million AUD | 250.29% |
| 2023 Q4 | 1.9 Million AUD | -53.91% |
| 2023 Q3 | 4.13 Million AUD | -38.07% |
| 2022 FY | 1.9 Million AUD | -55.94% |
| 2022 Q2 | 2.56 Million AUD | 0.0% |
| 2022 Q3 | 1.9 Million AUD | -25.64% |
| 2022 Q1 | 2.56 Million AUD | -40.75% |
| 2022 Q4 | 1.9 Million AUD | 0.0% |
| 2021 Q3 | 4.32 Million AUD | -18.68% |
| 2021 Q4 | 4.32 Million AUD | 0.0% |
| 2021 Q1 | 5.32 Million AUD | -32.02% |
| 2021 FY | 4.32 Million AUD | -44.72% |
| 2021 Q2 | 5.32 Million AUD | 0.0% |
| 2020 Q2 | 8.81 Million AUD | 0.0% |
| 2020 FY | 7.82 Million AUD | 33.62% |
| 2020 Q4 | 7.82 Million AUD | 0.0% |
| 2020 Q1 | 8.81 Million AUD | 50.51% |
| 2020 Q3 | 7.82 Million AUD | -11.22% |
| 2019 FY | 5.85 Million AUD | 261.72% |
| 2019 Q1 | 7.11 Million AUD | 339.55% |
| 2019 Q2 | 7.11 Million AUD | 0.0% |
| 2019 Q4 | 5.85 Million AUD | 0.0% |
| 2019 Q3 | 5.85 Million AUD | -17.71% |
| 2018 Q3 | 1.61 Million AUD | -2.45% |
| 2018 Q4 | 1.61 Million AUD | 0.0% |
| 2018 Q2 | 1.65 Million AUD | 0.0% |
| 2018 Q1 | 1.65 Million AUD | -19.41% |
| 2018 FY | 1.61 Million AUD | -21.38% |
| 2017 Q4 | 2.05 Million AUD | 0.0% |
| 2017 Q3 | 2.05 Million AUD | 37.61% |
| 2017 Q2 | 1.49 Million AUD | 0.0% |
| 2017 Q1 | 1.49 Million AUD | -57.03% |
| 2017 FY | 2.05 Million AUD | -40.87% |
| 2016 Q3 | 3.48 Million AUD | -4.36% |
| 2016 FY | 3.48 Million AUD | -24.54% |
| 2016 Q2 | 3.64 Million AUD | 0.0% |
| 2016 Q1 | 3.64 Million AUD | -21.1% |
| 2016 Q4 | 3.48 Million AUD | 0.0% |
| 2015 Q2 | 3.14 Million AUD | 0.0% |
| 2015 FY | 4.61 Million AUD | 147.66% |
| 2015 Q4 | 4.61 Million AUD | 0.0% |
| 2015 Q3 | 4.61 Million AUD | 46.96% |
| 2015 Q1 | 3.14 Million AUD | 68.52% |
| 2014 FY | 1.86 Million AUD | -61.7% |
| 2014 Q4 | 1.86 Million AUD | 0.0% |
| 2014 Q3 | 1.86 Million AUD | -16.33% |
| 2014 Q1 | 2.22 Million AUD | -54.22% |
| 2014 Q2 | 2.22 Million AUD | 0.0% |
| 2013 Q3 | 4.86 Million AUD | 0.0% |
| 2013 Q4 | 4.86 Million AUD | 0.0% |
| 2013 FY | 4.86 Million AUD | -42.49% |
| 2012 FY | 8.46 Million AUD | 219.96% |
| 2012 Q4 | 8.46 Million AUD | 0.0% |
| 2011 Q4 | 2.64 Million AUD | 0.0% |
| 2011 FY | 2.64 Million AUD | 42.35% |
| 2010 FY | 1.85 Million AUD | 74.64% |
| 2010 Q4 | 1.85 Million AUD | 0.0% |
| 2009 Q4 | 1.06 Million AUD | 0.0% |
| 2009 FY | 1.06 Million AUD | -53.08% |
| 2008 Q4 | 2.26 Million AUD | 0.0% |
| 2008 FY | 2.26 Million AUD | 49.26% |
| 2007 Q4 | 1.51 Million AUD | 0.0% |
| 2007 FY | 1.51 Million AUD | -68.45% |
| 2006 FY | 4.81 Million AUD | 98.22% |
| 2006 Q4 | 4.81 Million AUD | 0.0% |
| 2005 FY | 2.42 Million AUD | -21.89% |
| 2005 Q4 | 2.42 Million AUD | 0.0% |
| 2004 FY | 3.1 Million AUD | -47.38% |
| 2004 Q4 | 3.1 Million AUD | 0.0% |
| 2003 Q4 | 5.9 Million AUD | 0.0% |
| 2003 FY | 5.9 Million AUD | -31.55% |
| 2002 Q4 | 8.63 Million AUD | 0.0% |
| 2002 FY | 8.63 Million AUD | -15.3% |
| 2001 FY | 10.19 Million AUD | -75.86% |
| 2001 Q4 | 10.19 Million AUD | 0.0% |
| 2000 FY | 42.22 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 98.73% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 93.165% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.54% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 95.324% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.621% |
| Mesoblast Limited | 667.9 Million USD | 99.926% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -581.926% |
| Genus plc | 1.02 Billion USD | 99.952% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 63.671% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 1.115% |
| Marizyme, Inc. | 22.01 Million USD | 97.758% |
| ContraFect Corporation | 20.67 Million USD | 97.614% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 21.296% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -26.414% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -29.122% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 65.54% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 88.098% |
| MultiCell Technologies, Inc. | 126.22 USD | -390864.982% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 47.485% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.616% |
| EV Biologics, Inc. | 431.71 Thousand USD | -14.306% |
| Q BioMed Inc. | 3.51 Million USD | 85.963% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 98.597% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 35.966% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -88.871% |
| Biomind Labs Inc. | 73.81 Thousand USD | -568.495% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 99.893% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 98.356% |
| Skye Bioscience, Inc. | 11.94 Million USD | 95.867% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 85.105% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 82.031% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 74.799% |
| IMV Inc. | 31.33 Million USD | 98.425% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 28.22% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 81.043% |
| GB Sciences, Inc. | 103.44 Thousand USD | -377.056% |
| Alpha Cognition Inc. | 2.45 Million USD | 79.876% |
| HST Global, Inc. | 1526.00 USD | -32237.877% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Halberd Corporation | 10.13 Thousand USD | -4770.951% |
| Enzolytics Inc. | 361.7 Million USD | 99.864% |
| Resverlogix Corp. | 8.11 Million USD | 93.919% |
| Affymax, Inc. | 7.44 Million USD | 93.37% |
| SYBLEU INC | 330.46 Thousand USD | -49.326% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 73.722% |
| argenx SE | 4.54 Billion USD | 99.989% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 98.234% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 98.966% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -2066.174% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 94.486% |
| AVAX Technologies, Inc. | 7.37 Million USD | 93.311% |
| Zenith Capital Corp. | 7410.00 USD | -6559.595% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.985% |
| Ember Therapeutics, Inc. | 184.00 USD | -268093.478% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -53.346% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -88.808% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.889% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 65.94% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | 83.687% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.064% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 46.821% |
| BioStem Technologies, Inc. | 14.56 Million USD | 96.611% |
| ONE Bio Corp. | 70.08 Million USD | 99.296% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -764.322% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -21262.597% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 50.051% |
| Agentix Corp. | 261.39 Thousand USD | -88.788% |
| LadRx Corporation | 2.3 Million USD | 78.618% |
| Cell Source, Inc. | 195.17 Thousand USD | -152.843% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -2.688% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -39.551% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -39.551% |
| NovAccess Global Inc. | 62.24 Thousand USD | -692.758% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 22.853% |
| Itoco Inc. | 1.4 Million USD | 64.754% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -415.881% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -365.543% |
| Kadimastem Ltd | 2.3 Million USD | 78.583% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -546.3% |
| CytoDyn Inc. | 11.13 Million USD | 95.569% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -245.156% |
| Mobile Lads Corp. | 52.00 USD | -948892.308% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -2659.933% |
| Qrons Inc. | 420.00 USD | -117394.286% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -28.019% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 10.622% |
| Rebus Holdings, Inc. | 5000.00 USD | -9769.52% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -20.53% |
| International Stem Cell Corporation | 5.39 Million USD | 90.845% |
| Bioxytran, Inc. | 137.63 Thousand USD | -258.532% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 96.711% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 97.023% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -524.653% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 42.929% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 93.435% |
| Neutra Corp. | 2851.00 USD | -17208.874% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 98.477% |
| PureTech Health plc | 693.97 Million USD | 99.929% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 93.886% |
| IXICO plc | 15.84 Million USD | 96.885% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 94.042% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.522% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.852% |